HUMA · Humacyte, Inc.
AI read · Good for HUMA
The AI's read
That filing gives ATEV a chance to gain a second approved use, beyond its existing approval for extremity vascular trauma. Three Phase 3 trials support the application, and one found women reached functional access faster than with traditional options. The FDA has not approved this use, so sales from dialysis access are not yet established.